12:00 AM
 | 
Sep 24, 2012
 |  BC Week In Review  |  Company News  |  Other News

Boehringer Ingelheim infectious news

Boehringer said it will discontinue its virology research program following a review of its research areas and priorities. The company said, "the demands for medical innovation are shifting significantly" in virology due to the availability of new medicines and an emphasis on prevention through vaccination, a field in which Boehringer is not active. Boehringer expects the discontinuation of its virology research program to affect about 170 employees, due...

Read the full 319 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >